title: Gallstone dissolution therapy with ursodiol. Patient selection.
abstract: Ursodeoxycholic acid (ursodiol) has been shown to be an effective oral agent for dissolution of gallstones that also has a favorable safety profile. In the selection of patients as candidates for this treatment, stone characteristics and the functional status of the gallbladder are the two most important criteria. Small, primarily cholesterol stones (radiolucent on plain film) are the most suitable for oral dissolution therapy. In addition, a functioning gallbladder (as evidenced by visualization on oral cholecystogram) is required to concentrate the ursodiol-enriched bile and effect stone dissolution. Ursodiol should not be used during pregnancy, in women likely to become pregnant, or in severe acute or chronic intrahepatic cholestasis. Acute cholestasis and common bile duct obstruction also preclude this treatment. Screening tests include basic laboratory tests of liver function, sonographic evaluation of the gallbladder and biliary tree, plain film of the abdomen, and oral cholecystogram. Since few patients meet all the selection criteria ideally, the decision to undertake treatment with ursodiol must be based on the entire clinical profile and on the patient's willingness to accept the predicted likelihood of success.
authors.affiliation: Department of Medicine, George Washington University, Washington, D.C. 20037.
authors.forename: H
authors.initials: H
authors.lastname: Fromm
mesh_terms: D000367:Age Factors; D001835:Body Weight; D002769:Cholelithiasis / Q000032:analysis / Q000628:therapy*; D002784:Cholesterol / Q000032:analysis; D003840:Deoxycholic Acid / Q000031:analogs & derivatives*; D005704:Gallbladder / Q000503:physiopathology; D006801:Humans; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
chemical_list: D003840:Deoxycholic Acid; D014580:Ursodeoxycholic Acid; D002784:Cholesterol